|
 |
Nazwa handlowa |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Adwigmine |
Egipt |
|
Amostigmine |
Egipt |
|
Beemine |
Indie |
|
Epistigmine |
Egipt |
|
Fadastigmina |
Argentyna |
|
Ipostigmine |
Iran |
|
Miostin |
Rumunia |
|
Neostig |
Niemcy |
|
Neostigmin |
Niemcy, Szwecja |
|
Neostigmina |
Argentyna, Brazylia, Chile, Ekwador, Hiszpania, KolumbiaKolumbia, Peru, Portugalia, Wenezuela |
|
Neostigmine |
Arabia Saudyjska, Australia, Egipt, Grecja, Holandia, Irlandia, Kanada, Malezja, nowa Zelandia, Turcja, Wielka Brytania |
|
Normastigmin |
Austria |
|
Polstigminum |
Polska |
|
Prostigmin |
Austria, Belgia, Grecja, Holandia, Malezja, Szwajcaria |
|
Prostigmina |
Włochy |
|
Prostigmine |
Austria, Egipt, Francja , Hiszpania, KolumbiaKolumbia, Luksemburg, Maroko, Meksyk, Peru, Wenezuela, Zjednoczone Emiraty Arabskie |
|
Setisin |
Malezja |
|
Stigmosan |
Węgry |
|
Tigmin |
Peru |
|
Visulmin |
Meksyk |
|
|
 |
 |
Bibliografia : Neostigmine methylsulfate |
|
|
typ |
publikacja |
| 815 |
Czasopismo |
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634. |
| 1200 |
Czasopismo |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1228 |
Czasopismo |
Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381. |
| 1682 |
Czasopismo |
Storms M, Stewart JT, Warren FW.
Stability of neostigmine methylsulfate injection at ambient temperature and 4°C in polypropylene syringes.
Int J Pharm Compound 2002 ; 6: 475-477. |
| 2286 |
Czasopismo |
Ben M, Trusley C, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 4: 368-371. |
| 2291 |
Czasopismo |
Yeh MK.
Degradation kinetics of neostigmine in solution.
Drug Dev Ind Pharm 2000 ; 26, 11: 1221-1226. |
| 3372 |
Czasopismo |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
| 3578 |
Laboratorium |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3599 |
Laboratorium |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013 |
| 3644 |
Laboratorium |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 5003 |
Laboratorium |
NÉOSTIGMINE RENAUDIN 5 mg/5 mL, solution injectable - Résumé des caractéristiques du produit.
LABORATOIRE RENAUDIN 2019 |
|
|
